open access

Vol 14, No 1 (2011)
Original articles
Published online: 2011-07-12
Submitted: 2012-01-23
Get Citation

The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours

Grażyna Łapińska, Małgorzata Bryszewska, Agnieszka Fijołek-Warszewska, Izabella Kozłowicz-Gudzińska, Paweł Ochman, Agata Sackiewicz-Słaby
Nucl. Med. Rev 2011;14(1):16-20.

open access

Vol 14, No 1 (2011)
Original articles
Published online: 2011-07-12
Submitted: 2012-01-23

Abstract

BACKGROUND: Positron emission tomography (PET) combined with computer tomography (CT) using 68Ga-DOTATATE is a promising method for the evaluation of patients with recognised or suspected neuroendocrine tumours (NET). The aim of this study was to assess the diagnostic value of 68Ga-DOTATATE PET/CT in the visualisation of the expression of somatostatin receptors (SSTR) and identification of new lesions.
MATERIAL AND METHODS: Between December 2009 and January 2011 ninety-seven patients with confirmed (88 cases) or suspected (9 cases) NET underwent 68Ga DOTATATE PET/CT. The primary, confirmed or suspected, NET localizations were: GEP tumours — 71 patients; medullary thyroid carcinoma — 4 patients; cancer of an unknown primary — 14 patients; and NET in other localisations — 8 patients. PET/CT acquisitions were performed using standard techniques, 45 to 60 minutes after the intravenous injection of 111–185 MBq 68Ga-DOTATATE.
RESULTS: 68Ga-DOTATATE PET/CT detected the presence of lesions demonstrating the somatostatin receptor affinity in 50 of the 97 patients (51.5%) and was negative in 47 patients (48.5%). Among 14 patients with metastatic unknown primary cancer, in 5 patients (45.5%) the primary tumour site was identified, and in 4 patients with medullary thyroid cancer distant metastases with SSTR expression were localized in only one patient.
CONCLUSIONS: Our findings confirm the diagnostic role of 68Ga-DOTATATE PET/CT as an accurate method of identifying primary tumours and distant metastases. It provides information on tumour cell receptors status, which has a significant bearing on planning target radionuclide therapy. Overall, 68Ga-DOTATATE PET/CT can be used in staging, re-staging, and in regular follow up of oncology patients.
Nuclear Med Rev 2011; 14, 1: 16–20

Abstract

BACKGROUND: Positron emission tomography (PET) combined with computer tomography (CT) using 68Ga-DOTATATE is a promising method for the evaluation of patients with recognised or suspected neuroendocrine tumours (NET). The aim of this study was to assess the diagnostic value of 68Ga-DOTATATE PET/CT in the visualisation of the expression of somatostatin receptors (SSTR) and identification of new lesions.
MATERIAL AND METHODS: Between December 2009 and January 2011 ninety-seven patients with confirmed (88 cases) or suspected (9 cases) NET underwent 68Ga DOTATATE PET/CT. The primary, confirmed or suspected, NET localizations were: GEP tumours — 71 patients; medullary thyroid carcinoma — 4 patients; cancer of an unknown primary — 14 patients; and NET in other localisations — 8 patients. PET/CT acquisitions were performed using standard techniques, 45 to 60 minutes after the intravenous injection of 111–185 MBq 68Ga-DOTATATE.
RESULTS: 68Ga-DOTATATE PET/CT detected the presence of lesions demonstrating the somatostatin receptor affinity in 50 of the 97 patients (51.5%) and was negative in 47 patients (48.5%). Among 14 patients with metastatic unknown primary cancer, in 5 patients (45.5%) the primary tumour site was identified, and in 4 patients with medullary thyroid cancer distant metastases with SSTR expression were localized in only one patient.
CONCLUSIONS: Our findings confirm the diagnostic role of 68Ga-DOTATATE PET/CT as an accurate method of identifying primary tumours and distant metastases. It provides information on tumour cell receptors status, which has a significant bearing on planning target radionuclide therapy. Overall, 68Ga-DOTATATE PET/CT can be used in staging, re-staging, and in regular follow up of oncology patients.
Nuclear Med Rev 2011; 14, 1: 16–20
Get Citation

Keywords

68Ga-DOTATATE; PET/CT; neuroendocrine tumours

About this article
Title

The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours

Journal

Nuclear Medicine Review

Issue

Vol 14, No 1 (2011)

Pages

16-20

Published online

2011-07-12

Bibliographic record

Nucl. Med. Rev 2011;14(1):16-20.

Keywords

68Ga-DOTATATE
PET/CT
neuroendocrine tumours

Authors

Grażyna Łapińska
Małgorzata Bryszewska
Agnieszka Fijołek-Warszewska
Izabella Kozłowicz-Gudzińska
Paweł Ochman
Agata Sackiewicz-Słaby

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl